AUROBINDO PHARMA
Quarterly Results Analysis [Sep2024]
AUROBINDO PHARMA Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹7,796 Cr | ₹7,567 Cr | ₹7,580 Cr | ₹7,352 Cr | ₹7,219 Cr | ₹6,851 Cr | ₹6,473 Cr | ₹6,407 Cr |
Expenses | ₹6,230 Cr | ₹5,947 Cr | ₹5,907 Cr | ₹5,750 Cr | ₹5,846 Cr | ₹5,699 Cr | ₹5,471 Cr | ₹5,453 Cr |
Operating Income | ₹1,566 Cr | ₹1,620 Cr | ₹1,673 Cr | ₹1,601 Cr | ₹1,373 Cr | ₹1,151 Cr | ₹1,002 Cr | ₹954 Cr |
Other Income | ₹136 Cr | ₹221 Cr | ₹136 Cr | ₹163 Cr | ₹187 Cr | ₹116 Cr | ₹135 Cr | ₹93 Cr |
Interest | ₹113 Cr | ₹111 Cr | ₹89 Cr | ₹76 Cr | ₹68 Cr | ₹57 Cr | ₹56 Cr | ₹45 Cr |
Depreciation | ₹382 Cr | ₹404 Cr | ₹354 Cr | ₹423 Cr | ₹418 Cr | ₹327 Cr | ₹346 Cr | ₹321 Cr |
Profit Before Tax | ₹1,207 Cr | ₹1,325 Cr | ₹1,243 Cr | ₹1,265 Cr | ₹1,075 Cr | ₹815 Cr | ₹736 Cr | ₹681 Cr |
Profit After Tax | ₹817 Cr | ₹920 Cr | ₹920 Cr | ₹943 Cr | ₹751 Cr | ₹573 Cr | ₹512 Cr | ₹492 Cr |
EPS | ₹14.07 | ₹15.69 | ₹15.51 | ₹15.98 | ₹12.92 | ₹9.74 | ₹8.64 | ₹8.38 |
Industry Peers & Returns | 1W | 1M | 1Y |
AUROBINDO PHARMA | -0.4% | 1.7% | 22.9% |
SUN PHARMACEUTICAL INDUSTRIES | -0.1% | 1.7% | 45.7% |
CIPLA | 1.7% | 0.5% | 23.7% |
DR REDDYS LABORATORIES | 5.7% | 12.4% | 18.5% |
ZYDUS LIFESCIENCES | -1.4% | 3.1% | 44.8% |
DIVIS LABORATORIES | -0.1% | -2.2% | 56.9% |
MANKIND PHARMA | 4.2% | 9.8% | 49.8% |
TORRENT PHARMACEUTICALS | 2.2% | 10.6% | 61.7% |
LUPIN | 4.1% | 5.1% | 71.7% |
AUROBINDO PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 3.03 % |
Y-o-Y | 7.99 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹7,796 Cr | 3.03 | |
Jun2024 | ₹7,567 Cr | -0.17 | |
Mar2024 | ₹7,580 Cr | 3.11 | |
Dec2023 | ₹7,352 Cr | 1.83 | |
Sep2023 | ₹7,219 Cr | 5.38 | |
Jun2023 | ₹6,851 Cr | 5.83 | |
Mar2023 | ₹6,473 Cr | 1.03 | |
Dec2022 | ₹6,407 Cr | - |
AUROBINDO PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -3.30 % |
Y-o-Y | 14.03 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹1,566 Cr | -3.30 | |
Jun2024 | ₹1,620 Cr | -3.18 | |
Mar2024 | ₹1,673 Cr | 4.47 | |
Dec2023 | ₹1,601 Cr | 16.59 | |
Sep2023 | ₹1,373 Cr | 19.29 | |
Jun2023 | ₹1,151 Cr | 14.89 | |
Mar2023 | ₹1,002 Cr | 5.01 | |
Dec2022 | ₹954 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -6.12 % |
Y-o-Y | 5.63 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 20.09% | -6.12 | |
Jun2024 | 21.4% | -3.04 | |
Mar2024 | 22.07% | 1.33 | |
Dec2023 | 21.78% | 14.51 | |
Sep2023 | 19.02% | 13.15 | |
Jun2023 | 16.81% | 8.59 | |
Mar2023 | 15.48% | 3.89 | |
Dec2022 | 14.9% | - |
AUROBINDO PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -11.20 % |
Y-o-Y | 8.74 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹817 Cr | -11.20 | |
Jun2024 | ₹920 Cr | -0.04 | |
Mar2024 | ₹920 Cr | -2.39 | |
Dec2023 | ₹943 Cr | 25.50 | |
Sep2023 | ₹751 Cr | 31.18 | |
Jun2023 | ₹573 Cr | 11.87 | |
Mar2023 | ₹512 Cr | 4.10 | |
Dec2022 | ₹492 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -13.74 % |
Y-o-Y | 0.77 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 10.48 % | -13.74 | |
Jun2024 | 12.15 % | 0.08 | |
Mar2024 | 12.14 % | -5.30 | |
Dec2023 | 12.82 % | 23.27 | |
Sep2023 | 10.4 % | 24.40 | |
Jun2023 | 8.36 % | 5.69 | |
Mar2023 | 7.91 % | 3.13 | |
Dec2022 | 7.67 % | - |
AUROBINDO PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -10.33 % |
Y-o-Y | 8.90 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹14.07 | -10.33 | |
Jun2024 | ₹15.69 | 1.16 | |
Mar2024 | ₹15.51 | -2.94 | |
Dec2023 | ₹15.98 | 23.68 | |
Sep2023 | ₹12.92 | 32.65 | |
Jun2023 | ₹9.74 | 12.73 | |
Mar2023 | ₹8.64 | 3.10 | |
Dec2022 | ₹8.38 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD